summarized stringlengths 41 385 |
|---|
Previous studies evaluating influence statins survival patients diffuse large B cell lymphoma (DLBCL) showed inconsistent results . This systematic review meta-analysis conducted investigate whether statin use correlated survival . |
CD19-directed CAR T cells greatly improved outcomes B-cell malignancies, significant limitations therapy . CD19-directed CAR T cells greatly improved outcomes B-cell malignancies, significant limitations therapy . |
Regulatory T cells (Tregs) induce immune responses may contribute immune escape tumors . Accumulation Tregs tumors represents critical barrier anti-tumor immunity immunotherapy . |
Germinal center B (GCB) cells provide niche support development angioimmunoblastic T-cell lymphoma . |
Subclones drive Richter transformation (RT) chronic lymphocytic leukemia seeded early . Subclones drive Richter transformation (RT) chronic lymphocytic leukemia seeded early . |
Diffuse large B cell lymphoma (DLBCL) one usual types adult lymphoma heterogeneousness . We systematically explored DLBCL gene expression dataset provided publicly available clinical information patients GEO . In research, 928 DLBC |
Recent evidence shown exosomes deliver siRNA tumor tissues mice . Here, reduce immunogenicity, selected immature dendritic cells (DCs) produce exosomes . |
Diffuse large B-cell lymphoma (DLBCL) curable first-line chemoimmunotherapy patients relapsed/refractory (R/R) DLBCL still face poor prognosis . CD19- |
B-cell lymphoma, unclassifiable, features intermediate diffuse large B-cell lymphoma classical Hodgkin lymphoma classical Hodgkin lymphoma classical Hodgkin lymphoma (BCLu-DLBCL/cHL) Also referred |
We used hospital-based cancer registry data in Japan to extract cases adrenal malignancies histologically confirmed, diagnosed, initially treated 2012-2015 . For survival analysis, used data 2008-2009 cohort estimate 5-year overall survival ( |
CAR-T cell therapy emerged effective treatment refractory hematological malignancies . Hospital-wide retrospective study included 71 patients requiring ICU admission July 2017 December 2020 included 71 patients (median age 60 years [37-68 |
Primary breast lymphoma (PBL) rare malignant breast tumor . Study aimed elucidate sonographic characteristics PBL explore value ultrasonography preoperative diagnosis PBL using Breast Imaging Reporting Data System (BI-RADS) |
This study assessed impact adherence guidelines-recommended diagnostic testing treatment selection overall survival (OS) patients diffuse large B-cell lymphoma (DLBCL) initiated rituximab-based first line treatment (1-LOT |
Axicabtagene ciloleucel (axi-cel) found superior clinical outcomes compared standard care (SOC) second-line large B-cell lymphoma (2L LBCL) second-line large |
Diffuse large B cell lymphoma, otherwise specified (DLBCL, NOS) common type non-Hodgkin lymphoma (NHL) Diffuse large B cell lymphoma, otherwise specified (DLBCL, |
Non-Hodgkin lymphoma (NHLHL) haematolymphoid neoplasm affect nodal extra-nodal sites . It rare disease oral cavity, accounting 2% extra-nodal lymph |
Renal manifestations associated associated hematolymphoid malignancies known . Renal manifestations associated hematolymphoid malignancies known . |
Marginal zone lymphoma (MZL) rare, slow-growing/indolent B cell lymphoid neoplasm accounting 10.5% 11.8% B cell lymphomas . MZL originates mature B |
Diffuse large B-cell lymphoma (DLBCL) frequently occurring subtype lymphoma . Fundamental processes underlying pathogenesis of DLBCL remain little understood . |
AI-based tool rapidly extracts FDG-PET imaging metrics DLBCL . On availability scan, combination clinical data, approach generates clinically informative risk scores . Overall, 1268 patients previously untreated DLBCL phase III GOYA trial ( |
N-methyl-D-aspartate receptor (NMDAR) ionotropic glutamate (Glu) receptor widely expressed central nervous system (CNS) We present case patient atypical clinical manifestations positive anti-NMDAR |
Plasmablastic lymphoma (PBL) aggressive rare subtype non-Hodgkin lymphoma standard-of-care therapy . |
Germinal center-derived lymphomas follicular lymphoma (FL) diffuse large B cell lymphoma (DLBCL) characterized frequent mutations histone-modifying genes . Epigenetic mechanisms DNA hypermethylation and histone |
Zanubrutinib, next-generation non-covalent Bruton's tyrosine kinase (BTK) inhibitor, shows great efficacy treatment B cell malignancies . Some patients may experience series side effects treatment |
Richter transformation (RT) paradigmatic evolution of chronic lymphocytic leukemia (CLL) aggressive large B cell lymphoma conferring dismal prognosis . The mechanisms driving RT remain largely unknown . |
An estimated 30-40% patients diffuse large B cell lymphoma (DLBCL) either relapse refractory disease first-line chemoimmunotherapy . CD19-targeted chimeric antigen receptor (CAR) T- |
Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) total knee arthroplasty (TKA) rare . We described case PCDLBCL TKA, whose cutaneous mass develops around surgical sites, |
Little known presence existence existence existence of diffuse large B-cell lymphoma (DLBCL) Little known presence existence of little known presence existence of diffuse large B-cell lymphoma (DLBCL) |
A 53-year-old male presented 1-month history hyperpyrexia . The clinical manifestations revealed hemophagocytic lymphohistiocytosis (HLH) After treated HLH-1994 (dexam |
40% of patients with diffuse large B-cell lymphoma experience relapse refractory disease . Despite effectiveness immuno-chemotherapy, 40% patients experience relapse refractory disease . |
Vitamin D insufficiency potentially modifiable risk factor poor outcomes newly diagnosed large B-cell lymphoma (LBCL) Role circulating vitamin D concentrations relapsed/refractory LBCL treated CD19-directed chimeric antigen |
Extranodal diffuse B cell lymphoma (DBCL) represents 30 58% non-Hodgkin's lymphoma . One major problems DBCL high likelihood disease relapse following treatment . |
Diffuse large B-cell lymphoma (DLBCL) aggressive type non-Hodgkin lymphoma . Many DLBCL patients poor prognosis . This study investigated key metabolism-related genes potential mechanisms . |
Protein phosphatase SHP-1 negatively regulates several oncogenic tyrosine kinases plays tumor suppressive role . Direct SHP-1 agonists used evaluate potential therapeutic implication SHP-1 DLBCL . |
Richter's Syndrome (RS) aggressive transformation CLL, usually clonally-related diffuse large B-cell lymphoma (DLBCL) characterized frequent TP53 mutations, intrinsic chemoresistance poor survival . TP53-independent |
HIV-1 matrix protein p17 found associated lymphoma development vitro . HIV-1 matrix protein p17 found associated lymphoma development vitro . HIV-1 p17 AIDS-related lymphoma. |
Neutrophil-to-lymphocyte ratio (NLR), biomarker systematic inflammation, confirmed prognostic factor many malignant diseases . Neutrophils lymphocyte subsets DLBCL patients dynamics along chemoimmun |
On rare occasions, secondary Epstein-Barr virus (EBV)-associated B-cell lymphoma develop patients angioimmunoblastic T-cell lymphoma (AITL) Here, describe tumor microenvironment mutation features patient |
Primary breast lymphoma (PBL) rare subtype non-Hodgkin's lymphoma (NHL) rapid progression high risk central nervous system metastasis . 16 sequenced target panel 112 genes related lymphoma . |
Type B lactic acidosis commonly seen hematological malignancies, especially lymphomas . It considered oncological emergency associated high mortality poor outcomes treated promptly . |
Diffuse large B-cell lymphoma (DLBCL) nowadays curable disease frontline treatment R-CHOP, 30-40% patients still unresponsive relapse thereafter . 30-40% patients still unresponsive relapse thereafter . New |
CD5-positive diffuse large B-cell lymphoma (DLBCL) clinically rare subtype DLBCL aggressive clinical manifestations poor prognosis . It demonstrated prognostic nutritional index (PNI), indicator nutritional status systemic inflammation, significant |
BCL10, key activator NF-κB downstream oncogenic B-cell receptor signaling, mutated nearly 40% BN2/C1 genetic subtype diffuse large B-cell lymphoma . |
R-CHOP standard first line therapy cures 60% patients . Salvage high-dose chemotherapy autologous stem cell transplant remains standard second-line treatment . |
In recent years, efficacy 5-aminolevulinic acid photodynamic diagnosis (5-ALA PDD) reported various types brain tumors, including malignant glioma . We report 17 consecutive patients intraventricular tumors . |
The case 53-year-old man diagnosed PCNSL tectal plate reported . The patient referred hospital 1-month history disorientation magnetic resonance imaging showed hydrocephalus enhancing lesion tectum . |
Amyloidoma, otherwise known tumoral amyloidosis, is localized deposition amyloid (AL-type AA type) without systemic amyloidosis . It rarest form tissue amyloid deposition, 7% am |
Biomarkers accurately predict outcome DLBCL patients urgently needed . Biomarkers accurately predict outcome DLBCL patients urgently needed . |
Primary immunodeficiencies (PIDs) acquired declines immune cell counts or/function . Secondary immunodeficiencies (SIDs) acquired declines immune cell counts or/function . The common type SID decreased antibody level occurring |
49-year-old man presented several-month history melena, unintentional weight loss . Further evaluation capsule endoscopy showed patchy erythematous mucosa jejunum creating suspicion Crohn's Disease . |
Kawasaki et al. provide hints that lymphoma cells exposed polatuzumab vedotin rituximab potential mechanism resistance . |
Diffuse large B-cell lymphoma (DLBCL) high-grade non-Hodgkin lymphoma increased incidence among people living HIV-infection (PLWH) Although frequency reportedly attenuated antiretroviral |
Dasatinib, second-generation tyrosine kinase inhibitor (TKI), used treatment chronic myeloid leukemia, BCR::ABL1-positive (CML) Complicated pleural pericardial effusions |
Mice overexpressing BCL6 B cell-specific immunoglobulin heavy chain . chain μ intron promoter (Iμ-Bcl6<sup>Tg/+</sup> mice develop B cell lymphomas |
Gemcitabine-based regimens effective salvage therapy RR lymphoma patients eligible ASCT, limited data transplant-ineligible (TIE) patients . We identified 33 patients: 54.5% diffuse large Bcell lymphoma ( |
Axicabtagene ciloleucel (axi-cel) improved event-free survival (EFS) compared standard care (SOC) salvage chemoimmunotherapy followed autologous stem cell transplant . Study |
Real-world evidence comparing efficacy chimeric antigen receptor (CAR) T-cell therapy previous standard care (SOC) refractory large B-cell lymphoma (LBCL) scarce . We observed superior effi. We |
CAR T cell therapy transformed salvage approach relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) Maintaining disease control CAR T cell infusion product manufacturing (so-called bridging therapy) |
Richter transformation (RT) development high-grade lymphoma patients B-cell chronic lymphocytic leukemia (CLL) small lymphocytic lymphoma (SLL) A small percentage CLL patients develop aggressive histologic transformation diffuse |
HIV-associated lymphoma (HAL) common malignancy South Africa . Due high prevalence HIV, HIV, HIV-associated lymphoma (HAL) common malignancy . However, paucity literature literature has been lacking |
Adult kidney transplant recipient developed diffuse large B cell lymphoma distal ureter setting new allograft nephropathy . Early intervention, reduction immunosuppression, surgical reconstruction chemotherapy salvaged allograft kidney averted fatal |
Diffuse large B-cell lymphoma (DLBCL) common non-Hodgkin's lymphoma (NHL) accounts approximately 25% NHLs developed countries . Most patients present advanced disease 60% presenting stage 3 4 |
Primary central nervous system lymphoma (PCNSL) rare cranial malignant haematological tumour . We report 3 cases cerebellar PCNSL underwent neuronavigation microsurgery . The operation performed author 3 author |
Data describing progression events incomplete long-term survival outcomes yet established . In patients with B-cell cancer, diffuse large B-cell lymphoma (DLBCL), heterogeneous clinical efficacy outcomes observed presence 'cured' (long- |
55-year-old female referred recurrent unilateral anterior hypopyon anterior uveitis . All laboratory tests, review systems ocular sampling results unremarkable . |
B-cell non-Hodgkin's lymphoma includes several subtypes, notably Diffuse Large B-Cell Lymphoma (DLBCL) Each presentation defining characteristic, CD5 positivity notoriously known poor prognostic factor |
High-dose methotrexate administered concurrently R-CHOP (RM-CHOP) commonly used regimen, data outcomes achieved regimen limited . |
Chimeric antigen receptor (CAR) T-cell therapy revolutionized treatment various B-cell malignancies . However, cause serious adverse effects like immune effector cell-associated neurotoxicity syndrome (ICANS) ICANS attributed disruption |
Post-transplant lymphoproliferative disorder (PTLD) heterogeneous lymphoid cell disorder occurs solid organ hematopoietic stem cell transplantation . We present rare case PCNS-PTLD misdiagnosed gl |
Clonal hematopoiesis indeterminate potential (CHIP) common patients hematologic malignancies . Recent publications provide evidence CHIP may affect chimeric antigen receptor T-cell therapy efficacy . |
Primary cutaneous peripheral T-cell lymphomas T-follicular helper phenotype (pcTFH-PTCL) poorly characterized . Often compared to, corresponding with, mycosis fungoides (MF), Séz |
Odronextamab CD20 × CD3 bispecific antibody demonstrated durable responses manageable safety profile patients R/R B-NHL first-in-human trial . |
Disulfide (DSF) shown anticancer effects, effect DLBCL remains unclear . B-cell lymphoma 6 (BCL6) oncogene required survival required survival . |
Lymphoma conjunctiva ocular malignancy derived clonal proliferation lymphocytes . Majority conjunctival lymphoma extranodal marginal zone B-Cell lymphoma (EMZL) Majority conjunctival lymphoma ext |
APRIL BAFF receptor activity was neutralizing TNF receptor ligands APRIL BAFF receptor activity . It impacted protein translation production of MM cells . It modulates translation efficiency ATM interactor (ATMIN/ACSIZ) |
Review highlights recent studies furthering clinical development of selinexor . Selinexor, novel exportin-1 inhibitor, treatment multiple myeloma non-Hodgkin lymphomas . |
Diffuse large B-cell lymphoma (DLBCL) aggressive lymphoma variable clinical outcomes prediction prognosis remains important long-term remission . We performed serial serum soluble interleukin-2 receptor (sIL-2R |
The endothelial activation stress index (EASIX) score reported predict overall survival (OS) hematological cancers . However, validated prognostic marker diffuse large B-cell lymphoma (DLBCL) date was reviewed . |
We retrospectively analyzed SARS-CoV-2 vaccination antibody responses cohort 273 patients lymphoproliferative disorders plasma cell dyscrasias seen single tertiary cancer center . We found antibody response rate SARS-CoV- |
Primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) uncommon non-Hodgkin lymphoma subtype, clinical pathological characteristics remain unclear . PCNS-DLBCL patient data retrospectively |
Diffuse large B-cell lymphoma (DLBCL) biologically clinically clinically heterogeneous disease requires personalized clinical treatment . Cyogenetic abnormalities genetic mutations widely applied prognostic stratification DLBCL . Increasing evidence demonstrated deregulated epigenetic |
Immunotherapy T cells genetically modified chimeric antigen receptors (CARs) shown significant clinical efficacy patients relapsed/refractory B-cell lymphoma . 50% treated patients benefit therapy due either absence response relapse or relapse . Eluc |
Primary brainstem lymphoma (PBSL) rare malignant. An understanding disease lacking. We aimed characterize clinical features, estimate survival, explore survival-related factors PBSL. |
Adriamycin (doxorubicin) important traditional drug exhibits cytotoxicity Diffuse Large B-cell Lymphoma (DLBCL) Doxorubicin affects DLBCL cells stages cell cycle |
Diffuse large B-cell lymphoma (DLBCL) represents frequent lymphoma adults . Prognosis DLBCL patients may evaluated prominent clinical/laboratory parameters pattern gene expression . |
Diffuse Large Bcell Lymphoma (DLBCL) is a relapsed/refractory setting . Of 7,877 patients DLBCL, 367 patients DHL 61 were treated with CAR Tcell therapy . |
Diffuse large B cell lymphoma comprises heterogeneous group B cell-derived tumors, different degrees aggressiveness, defined cellular origin tissue microenvironment . Study demonstrate lymphoma cells display surface phenotype, IgH V-region somatic mutations, |
Primary vitreoretinal lymphoma great masquerader provides diagnostic challenge . Steroid treatment presumed uveitis interfere correct diagnosis vitreoretinal lymphoma . |
The larynx rare site extranodal non-Hodgkin lymphoma (NHL) accounting less 1% primary laryngeal neoplasms . The larynx rare site extranodal non- |
Axicabtagene ciloleucel (Yescarta) approved use of second-line drug for large B-cell lymphoma resistant to, relapse within 12 months of, first-line chemoimmunotherapy . |
Tafasitamab lenalidomide approved second-line treatment diffuse large B-cell lymphoma (DLBCL) based single-arm phase II study . This combination superior routine immunochemotherapy regimens comparing matched observational |
We performed retrospective analysis 1767 DLBCL patients . We found patients hyperglycemia tend higher age (age>60 years) and hyperglycemia tend higher age (age>60 years) |
Lung collision tumor consisting squamous cell carcinoma lung diffuse large B-cell lymphoma extremely rare . Collision tumors consisting lung cancer malignant lymphoma extremely rare . |
Managing double-expressor lymphomas (DEL) controversial given dearth data lack standardized guidelines high-risk subset lymphomas . We performed largest analysis date exploring R-CHOP vs DA-EPOCH-R DEL . Adults |
This study compared efficacy, safety immunogenicity of ripertamab (SCT400) rituximab (Mabthera) and ripertamab (SCT400) rituximab |
Refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) patients' failure salvage chemotherapy extremely worse prognoses . Herein, 14 R/R DLBCL patients failed salvage |
Primary cutaneous lymphomas rare group diseases, estimated incidence 0.5-1 case per 100,000 people per year . Cutaneous B-cell lymphomas are rare group diseases, estimated incidence 0.5-1 case per 100 |
Immune checkpoint inhibitors may represent promising strategy boosting immune responses boosting immune responses . Studies suggest immune checkpoint inhibitors may represent promising strategy boosting immune responses . |
CC chemokine receptor 2 (CCR2) found involved tumor growth, angiogenesis, epithelial mesenchymal transition, metastasis, immune escape . CCR2 overexpression first identified poor prognostic predictor diffuse |
Wrist drop common presentation neurology. Wrist drop common presentation neurology. To localize lesion, clinicians focus testing finger extension, elbow flexion semipronated forearm, elbow extension among muscle groups identifying dermatomes numbness |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.